Victoria’s Secret Adopts Shareholder Plan
Victoria’s Secret & Co. (NYSE: VSCO) today announced that its Board of Directors has approved the adoption of a limited-duration shareholder rights plan to protect the best interests of all VS&Co shareholders. The Rights Plan is effective immediately and expires in one year.The Board, in consultation with its independent advisors, adopted the Rights Plan in response to the substantial accumulation of shares of VS&Co’s common stock by BBRC International Pte Limited, an entity controlled by Brett Blundy. In deciding to adopt the Rights Plan, the Board considered, among other things, that:Starting in March 2025, BBRC began increasing its position in VS&Co to approximately 13% of the outstanding shares;After nearly two years of reporting its beneficial ownership as a “passive investor” on Schedule 13G, in February 2024, BBRC began reporting on a Schedule 13D;BBRC made acquisitions of the Company’s common stock in violation of U.S. antitrust law for nearly three years by failing to file forms required under the Hart-Scott-Rodino Act and observe the regulatory waiting period, and now has made corrective filings that will enable BBRC to acquire up to 49.99% of the Company’s voting stock once the waiting period has expired, which we expect will be at 11:59 p.m., Eastern Time, on May 21.VSCO took on 20 cents when the market opened Tuesday to $22.99.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


